Cantor Fitzgerald Predicts PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ProQR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutical company will earn ($0.36) per share for the year. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

Other equities research analysts have also issued research reports about the company. JMP Securities reiterated a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Chardan Capital reaffirmed a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. Finally, Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

ProQR Therapeutics Stock Performance

PRQR opened at $2.23 on Wednesday. The stock has a market capitalization of $182.15 million, a PE ratio of -6.97 and a beta of 0.30. The company’s 50 day simple moving average is $3.06 and its 200 day simple moving average is $2.55. ProQR Therapeutics has a 1 year low of $1.61 and a 1 year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The business had revenue of $4.22 million during the quarter, compared to analysts’ expectations of $4.75 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ballentine Partners LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $61,000. OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after acquiring an additional 51,663 shares during the period. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).